SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247

SCYNEXIS Inc. (NASDAQ:SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS announced positive results from a Phase 1 clinical study evaluating SCY-247, its second-generation triterpenoid antifungal compound. The candidate is being developed for the treatment and prevention of invasive fungal infections to provide the therapeutic advantages of both an oral and an intravenous/IV formulation.

The favorable results show orally administered SCY-247 can achieve target exposures for efficacy with favorable tolerability, and at doses lower than their first-generation fungerp, which may offer a tolerability advantage. The Phase 1 study was conducted in healthy participants to assess the safety, tolerability, and pharmacokinetics of orally administered SCY-247. SCY-247 was well tolerated across all SAD and MAD cohorts.

The positive safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247. Further details from this study are expected to be presented at an upcoming scientific meeting.

SCYNEXIS Inc. (NASDAQ:SCYX) is a biotechnology company that develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the US.

While we acknowledge the potential of SCYX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.